Evidence map›Paper›PMID 35988522›Full record

Trial reportAmerican journal of otolaryngology

Efficacy of antiseptic mouthrinses against SARS-CoV-2: A prospective randomized placebo-controlled pilot study.

Paolo Junior Fantozzi, Emanuele Pampena, Alessandra Pierangeli, Giuseppe Oliveto, Leonardo Sorrentino, Domenico Di Vanna, Riccardo Pampena, Alessandro Lazzaro, Elio Gentilini, Claudio Maria Mastroianni and 4 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of otolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Paolo Junior FantozziDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, Italy.
Emanuele PampenaDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, Italy.
Alessandra PierangeliLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giuseppe OlivetoLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Leonardo SorrentinoLaboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Domenico Di VannaDepartment of Emergency Medicine, Umberto I Polyclinic Hospital, Sapienza University of Rome, Rome, Italy.
Riccardo PampenaCentro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Alessandro LazzaroInfectious Diseases Unit, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Elio GentiliniInfectious Diseases Unit, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Claudio Maria MastroianniInfectious Diseases Unit, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Gabriella D'EttorreInfectious Diseases Unit, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Antonella PolimeniDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, Italy.
Umberto RomeoDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, Italy. Electronic address: umberto.romeo@uniroma1.it.
Alessandro VillaDepartment of Orofacial Sciences, University of California San Francisco, San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCoronavirus-disease-19 (COVID-19) continues to affect millions of individuals worldwide. Antiviral activity of mouthrinses remains an important research area as the oral cavity is a site of SARS-CoV-2 initial replication. The aim of this study was to assess the effectiveness of three different mouthrinses in reducing the oral/oropharyngeal SARS-CoV-2 viral load.

methodsAdult patients, hospitalized with confirmed COVID-19 were recruited for the study. Oral/oropharyngeal baseline SARS-CoV-2 samples were collected and analyzed by Real-Time-PCR. Subsequently, patients were instructed to rinse with 1 % hydrogen peroxide (H

resultsIn the PVP-I 1 % group, 5/8 (62.5 %) patients at T1, and 3/8 (37.5 %) patients at T2, SARS-CoV-2 was not detectable in the swab specimens. In the H

conclusionsOral SARS-CoV-2 loads were reduced at T1 in the PVP-I 1 % and H CLINICAL RELEVANCE: PVP-I 1 % was the most effective rinse especially in patients with low viral copy numbers at baseline.

Indexed as

Anti-Infective Agents, LocalCOVID-19AdultAntiviral AgentsChlorhexidineHumansHydrogen PeroxidePilot ProjectsPovidone-IodineProspective StudiesSARS-CoV-2Sodium ChlorideAnti-Infective Agents, LocalAntiviral AgentsChlorhexidineHydrogen PeroxidePovidone-IodineSodium ChlorideChlorhexidineCOVID-19DisinfectionMouthOral cavityOral diseasesOral medicineOral rinsesPovidone‑iodinePublic healthSaliva

Identifiers

PMID35988522
PMCPMC9328839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.